Navigation Links
UT Southwestern researchers find drug-coated stents less risky for heart bypass patients
Date:1/21/2009

DALLAS Jan. 22, 2009 Coronary bypass surgery may carry less risk of serious complications if stents coated with a drug that suppresses cell growth are used in the procedure rather than bare-metal stents, UT Southwestern Medical Center researchers and colleagues have found.

The study, appearing online and in an upcoming issue of The Journal of the American College of Cardiology, is the first large, multicenter trial comparing two types of commonly used stents. Stents are small mesh tubes that reinforce the walls of blocked blood vessels. In this study, stents were used to treat blockages in diseased coronary arteries.

In bypass surgery, grafts are taken from the saphenous vein in the patient's thigh and sewn to the coronary arteries to help improve blood flow to the heart, relieve severe chest pain and reduce the risk of heart attacks from blocked arteries. Years after surgery, those grafts may develop blockages inside the graft that are challenging to treat because of high rates of recurrence.

"We wanted to see if one type of stent was superior in reducing the incidence of re-narrowing of the vein graft," said Dr. Emmanouil Brilakis, assistant professor of internal medicine at UT Southwestern and lead author of the study. "Stented vein grafts have a very high risk of re-narrowing sometimes up to 50 percent when bare metal stents are used.

"Drug-eluting stents could provide a solution to this problem, but limited clinical results have been reported to date. The drug-eluting stents examined in our study are coated with a medication called paclitaxel, which inhibits cell growth."

The drug coating is contained on a polymer that covers the surface of the stents and eventually elutes, or washes out of the stent, over a period of several months or years.

In the study, researchers examined 80 patients, roughly half of whom had vein grafts with drug-eluting stents and the other half who had the same procedure with bare-metal stents.

Researchers found that 51 percent of patients with the bare-metal stent had re-narrowing of the vein graft over several months compared with 9 percent of the drug-eluting stent group. In addition, 28 percent of patients who had a bare-metal stent required another procedure to treat the same blockage, while only 5 percent of patients who had the drug-eluting stent did.

Some previous studies have indicated that patients receiving drug-eluting stents in saphenous vein grafts may not reduce the risk of re-narrowing and may be associated with increased risk of death, Dr. Brilakis said.

"Our findings suggest that drug-eluting stents are a better choice than bare-metal stents for this type of procedure," he said. "Patients receiving paclitaxel-eluting stents in our study were significantly less likely to have recurrence of their graft blockage and to require repeat procedures. The rates of death were similar in both study groups, although our study was not designed to detect differences in mortality."

The researchers now hope to repeat the study in an expanded group of patients, which would provide important data to determine definitively the efficacy and safety of each kind of stent.


'/>"/>

Contact: Katherine Morales
katherine.morales@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. UT Southwestern University Hospitals transplant program recognized for increasing organ donor rates
2. Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert
3. Interferon needed for cells to remember how to defeat a virus, UT Southwestern researchers report
4. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
5. Cancer requires support from immune system to develop, UT Southwestern researchers report
6. Vaginal/Caesarean combo delivery of twins safe, UT Southwestern-led research finds
7. Steroids aid recovery from pneumonia, UT Southwestern researchers say
8. Superbug breast infections controllable in nursing mothers, UT Southwestern researchers find
9. UT Southwestern scientists discover leptin can also aid type 1 diabetics
10. Tiny molecule helps control blood-vessel development, UT Southwestern researchers find
11. UT Southwestern launches study of surgical option for treating diabetic and other neuropathies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
Breaking Medicine Technology: